{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Diseases&page=6", "query": { "condition": "Multiple Diseases", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 12225, "total_pages": 1223, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Diseases&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Diseases&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-05T16:51:26.974Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01383928", "title": "Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Ixazomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2011-10-31", "completion_date": "2017-11-27", "has_results": true, "last_update_posted_date": "2019-03-21", "last_synced_at": "2026-11-05T16:51:26.974Z", "location_count": 20, "location_summary": "Berkeley, California • Duarte, California • Stanford, California + 15 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01383928" }, { "nct_id": "NCT01597492", "title": "A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Belimumab plus Early Vaccination", "type": "BIOLOGICAL" }, { "name": "Belimumab plus Late Vaccination", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Human Genome Sciences Inc., a GSK Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2012-05-31", "completion_date": "2015-09-24", "has_results": true, "last_update_posted_date": "2018-08-16", "last_synced_at": "2026-11-05T16:51:26.974Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Paradise Valley, Arizona • Shreveport, Louisiana + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Shreveport", "state": "Louisiana" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Cumberland", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01597492" }, { "nct_id": "NCT02911571", "title": "PRospective Multiple Myeloma Impact Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "MMprofiler SKY92 gene signature", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "SkylineDx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2018-02-27", "completion_date": "2026-10-01", "has_results": false, "last_update_posted_date": "2026-04-28", "last_synced_at": "2026-11-05T16:51:26.974Z", "location_count": 9, "location_summary": "Washington D.C., District of Columbia • Atlanta, Georgia • Hackensack, New Jersey + 5 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Brooklyn", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02911571" }, { "nct_id": "NCT01278134", "title": "A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Copegus placebo", "type": "DRUG" }, { "name": "RO5024048", "type": "DRUG" }, { "name": "danoprevir", "type": "DRUG" }, { "name": "peginterferon alfa-2a [Pegasys]", "type": "DRUG" }, { "name": "ribavirin [Copegus]", "type": "DRUG" }, { "name": "ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 170, "start_date": "2011-02", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-11-05T16:51:26.974Z", "location_count": 18, "location_summary": "La Jolla, California • Sacramento, California • Orlando, Florida + 14 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT01278134" }, { "nct_id": "NCT07787156", "title": "Reach and Engagement of GENetic Education, Risk Assessment, and TEsting Feasibility Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma (PDAC)", "Family History of Pancreas Cancer", "Genetic Testing", "Multi-cancer Early Detection" ], "interventions": [ { "name": "Telephone education session", "type": "BEHAVIORAL" }, { "name": "Online educational materials", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2026-10-15", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-11-05T16:51:26.974Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07787156" }, { "nct_id": "NCT03110822", "title": "A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Ruxolitinib Oral Tablet [Jakafi]", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 134, "start_date": "2017-02-01", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2023-11-01", "last_synced_at": "2026-11-05T16:51:26.974Z", "location_count": 13, "location_summary": "Alhambra, California • Bakersfield, California • Encinitas, California + 9 more", "locations": [ { "city": "Alhambra", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03110822" }, { "nct_id": "NCT05826431", "title": "Cubii for Exercise in People With MS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Multiple Sclerosis", "Fatigue", "Activity, Motor", "Quality of Life" ], "interventions": [ { "name": "Cubii elliptical", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2023-04-19", "completion_date": "2023-12-04", "has_results": true, "last_update_posted_date": "2024-12-03", "last_synced_at": "2026-11-05T16:51:26.974Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05826431" }, { "nct_id": "NCT02261519", "title": "Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophrenia in Adults", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "NaBen®", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "SyneuRx International (Taiwan) Corp", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 280, "start_date": "2017-03-29", "completion_date": "2023-11-29", "has_results": false, "last_update_posted_date": "2024-05-24", "last_synced_at": "2026-11-05T16:51:26.974Z", "location_count": 1, "location_summary": "Pasadena, California", "locations": [ { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02261519" }, { "nct_id": "NCT00330265", "title": "Safety and Efficacy Study of an Interactive Wound Dressing (KC002) for the Treatment of Diabetic Foot Ulcers", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Foot Ulcer", "Diabetes" ], "interventions": [ { "name": "KC-002", "type": "DEVICE" }, { "name": "Conventional Wound Therapy", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "OTHER" ], "sponsor": "KeraCure", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2006-01", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2008-08-26", "last_synced_at": "2026-11-05T16:51:26.974Z", "location_count": 21, "location_summary": "Montgomery, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00330265" }, { "nct_id": "NCT05172466", "title": "Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Relapsing-remitting Multiple Sclerosis (RRMS)" ], "interventions": [ { "name": "BeCare application", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 0, "start_date": "2022-10-31", "completion_date": "2022-11-11", "has_results": false, "last_update_posted_date": "2022-11-25", "last_synced_at": "2026-11-05T16:51:26.974Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05172466" } ] }